CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 27, 2013--
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced that it has
been selected as a 2014
World Economic Forum Technology Pioneer. Agios is one of 36
companies selected for this recognition for its potential to transform
the future of business and society.
“We are incredibly honored to be recognized by the World Economic Forum
along with 35 other companies that hope to impact the health and
technology industries on a global scale,” said David Schenkein, M.D.,
chief executive officer at Agios. “As a Technology Pioneer, we have the
unique opportunity to engage with companies and individuals from around
the world and share our novel approach to creating medicines that we
believe can have a potentially transformative effect on patients.”
Each year the World Economic Forum chooses a select number of Technology
Pioneers from hundreds of applicants. Candidate companies are nominated
by members, constituents and collaborators of the World Economic Forum
and by the public. A selection committee comprised of top technology and
innovation experts, academics and venture capitalists reviews all
applications before making its recommendation to the World Economic
Forum.
The Technology Pioneers will be recognized for their achievements in a
ceremony on September 12, 2013 at the Annual Meeting of the New
Champions 2013 in Dalian, People’s Republic of China. The meeting is the
foremost global business gathering in Asia, which brings together
leaders from top-ranked multinationals and chief executive officers of
dynamic and fast-growing companies. More information about the World
Economic Forum’s Technology Pioneers program along with the full list of
winners can be found at http://www.weforum.org/techpioneers.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and rare metabolic genetic diseases (known as
inborn errors of metabolism or IEMs) through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs
advancing toward the clinic. All Agios programs focus on genetically
identified patient populations leveraging our knowledge of metabolism,
biology and genomics. For more information, please visit our website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. The
words “hope,” “believe,” “expect” and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are subject
to important risks and uncertainties that may cause actual events or
results to differ materially from Agios’ current expectations and
beliefs, including the risks described under the caption “Risk Factors”
in Agios’ Registration Statement on Form S-1 which was declared
effective by the Securities and Exchange Commission (SEC) on July 23,
2013, and other filings that Agios may make with the SEC in the future.
Any forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any obligation
to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Source: Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick,
973-271-6085
dan@purecommunicationsinc.com
or
Investor
Contact:
Glenn Goddard
investors@agios.com
